[Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018011227
German
Original Title: Niraparib/Abirateronacetat (Prostatakarzinom)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a23-107.html
Year Published: 2024
URL for published report: https://www.iqwig.de/download/a23-107_niraparib-abirateronacetat_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A23-107
MeSH Terms
  • Prostatic Neoplasms
  • Prostatic Neoplasms, Castration-Resistant
  • Abiraterone Acetate
  • Antineoplastic Combined Chemotherapy Protocols
  • Poly(ADP-ribose) Polymerase Inhibitors
Keywords
  • Abiraterone Acetate
  • Niraparib
  • Prostatic Neoplasms – Castration-Resistant
  • Benefit Assessment
  • NCT03748641
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.